US006153615A

United States Patent [19]

Gross

[11] **Patent Number: 6,153,615**

[45] **Date of Patent: Nov. 28, 2000**

[54] **BLOCKING INDUCTION OF TETRAHYDROBIOTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS**

[75] Inventor: **Steven S. Gross**, New York, N.Y.

[73] Assignee: **Cornell Research Foundation, Inc.**, Ithaca, N.Y.

[21] Appl. No.: **09/228,977**

[22] Filed: **Jan. 12, 1999**

Related U.S. Application Data

[60] Continuation of application No. 08/642,883, May 6, 1996, Pat. No. 5,880,124, which is a division of application No. 08/151,889, Nov. 15, 1993, Pat. No. 5,872,177, which is a continuation-in-part of application No. 08/063,067, May 20, 1993, which is a continuation of application No. 07/813,507, Dec. 26, 1991, abandoned.

[51] **Int. Cl.**[7] **A61K 31/495**; A61K 31/405; A61K 31/195

[52] **U.S. Cl.** **514/253**; 514/415; 514/567

[58] **Field of Search** 514/253, 415, 514/567

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,557,106	1/1971	Roch	544/260 X
4,282,217	8/1981	Baglioni et al.	514/179
4,328,309	5/1982	Chambers et al.	435/126
4,670,438	6/1987	Austel et al.	514/249
4,701,455	10/1987	Nichol et al.	514/249
4,734,438	3/1988	Macri	514/653
5,002,944	3/1991	Spada et al.	514/221
5,028,627	7/1991	Kilbourn et al.	514/565
5,030,634	7/1991	Krumdieck et al.	514/249
5,059,712	10/1991	Griffith	562/560
5,132,453	7/1992	Griffith	562/560
5,158,883	10/1992	Griffith	435/240.2
5,196,195	3/1993	Griffith	424/94.6
5,216,025	6/1993	Gross et al.	435/126
5,273,875	12/1993	Griffith	435/1
5,281,627	1/1994	Griffith	514/564
5,298,506	3/1994	Stamler et al.	514/226.2
5,397,778	3/1995	Forse et al.	514/198
5,449,688	9/1995	Wahl et al.	514/546

FOREIGN PATENT DOCUMENTS

446699	9/1991	European Pat. Off. .
WO8404040	10/1984	WIPO .

OTHER PUBLICATIONS

Patent Cooperation Treaty International Search Report for PCT/US90/05199.

Stuehr, D.J., et al, Biochem. Biophys. Res. Commun. 161, 420–426 (1989).

Steuhr, D.J., et al, J. Exp. Med. 169, 1011–1020 (1989).

Rees, D.D., Proc. Natl. Acad. Sci. USA 86, 3375–3378 (1989).

Aisaka, K., et al, Biochem. Biophys. Res. Commun. 160, 881–886 (1989).

Natanson, C., et al, Journal of Exp. Med. 169, 823–832 (1989).

Schmidt, H., et al, Eur. J. Pharmacology, 154, 213–216 (1988).

Palmer, R.M.J., et al, Biochem. Biophys. Res. Commun. 153, 1251–1256 (1988).

Sakuma, I., et al, Proc. Natl. Acad. Sci. USA, 85, 8664–8667 (1988).

Palmer, R.M.J., et al, Nature, 333, 664–666 (1988).

Hibbs, J.B., et al, Biochem. Biophys. Res. Commun. 157, 87–94 (1988).

Marletta, M.A., et al, Biochemistry, 27, 8706–8711 (1988).

Palmer, R.M.J., et al, Nature, 327, 524–526 (1987).

Stuehr, D.J., et al, J. of Immunology, 139, 518–525 (1987).

Iyengar, R., et al, Proc. Nat'l. Acad. Sci. USA, 84, 6369–6373 (1987).

Turan, A., et al, Acta Chimica Academiae Scientiarum Hungaricae, 85, 327–332 (1975).

Kilbourn, R.G., et al, Proc. Nat'l. Acad. Sci. USA, 87, 3629–3632 (1990).

Kaufman, S., et al, J. Biol. Chem., 234, No. 10, 2683–2688 (Oct. 1959).

Kaufman, S., et al, J. Biol. Chem., 242, No. 17, 3934–3943 (Sep. 1967).

Kerler, F., et al, Exp. Cell Res., 189, 151–156 (1990).

Kwon, N.S., et al, J. Biol. Chem., 264, No. 34, 20496–20501 (Dec. 1989).

Milstien, S., et al, Biochem. Biophys. Res. Commun., 128, No. 3, 1099–1107 (May 1985).

Nichol, C., et al, Ann. Rev. Biochem. 54, 729–764 (1985).

Tayeh, M.A., et al, J. Biol. Chem., 264, No. 33, 19654–19658 (1989).

Werner–Felmayer, G., et al, J. Exp. Med., 172, 1599–1607 (1990).

Ziegler, I., et al., J. Biol. Chem., 265, No. 28, 17026–17030 (Oct. 1990).

Marletta, M.A., "Nitric oxide: biosynthesis and biological significance," name of publication unknown, Elsevier Science Publishers, Ltd. (UK), pp. 448–453 (1989).

(List continued on next page.)

Primary Examiner—Russell Travers

[57] **ABSTRACT**

Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with α_1-adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.

5 Claims, 9 Drawing Sheets